PUMD ProUroCare Medical Inc. featured news, full reports, and detailed charts
ProUroCare Medical Inc. (PUMD/PUMD.OB) Wrap Up:
ProUroCare Medical, Inc. is developing diagnostic equipment and treatments for enlarged prostates and other male urological conditions. It develops ProUroScan system, a mechanical imaging system that enables physicians to identify and characterize the existence of abnormal prostate tissue, and monitor changes in prostate tissue over time. This system produces a digital image of the prostate showing the size and symmetry of the prostate, as well as the location of soft-tissue abnormalities within the prostate. ProUroCare Medical has an agreement with Urologix, Inc. to co-develop products utilizing its electrical impedance tomography technology. The company was founded in 1999 and is based in ...www.prourocare.com
2 Employees
Founded in 1999
ProUroCare Medical Inc. (PUMD:OTC Bulletin Board Market)
LAST $2.21 USD
CHANGE TODAY +0.04 1.84%
VOLUME 23.5K
As of 3:48 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of ProUroCare Medical Inc. (PUMD)
|
OPEN
$2.17
|
PREVIOUS CLOSE
$2.17
|
|
|
DAY HIGH
$2.21
|
DAY LOW
$2.17
|
|
|
52 WEEK HIGH
11/20/09 - $2.21
|
52 WEEK LOW
12/26/08 - $0.41
|
|
|
MARKET CAP
24.7M
|
AVERAGE VOLUME 3 mo
13.8K
|
|
|
DILUTED EPS TTM
$-1.94
|
SHARES OUTSTANDING
11.2M
|
|
|
PUMD Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
PUMD Top Compensated Officers
Mr. Richard C. Carlson
Acting Chairman and Chief Executive Officer
Age: 58
Total Annual Compensation: $150.0K
Mr. Richard B. Thon
Chief Financial Officer, Principal Accounting...
Age: 54
Total Annual Compensation: $136.4K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for ProUroCare Medical Inc. (PUMD)
ProUroCare Medical Inc. Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
10/8/2009
ProUroCare Medical Inc. announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE). The results of the clinical study will be submitted to the U.S. Food and Drug Administration (FDA) in support of a 510(k) application in the near future after third party validation of the data.
ProUroCare Medical Inc. Adopts Amended Articles of Incorporation
08/17/2009
At the 2009 Annual Meeting of Shareholders of ProUroCare Medical Inc. held on August 11, 2009, the shareholders approved the adoption of the company's Amended Articles of Incorporation.
ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
08/11/2009
ProUroCare Medical Inc. announced that the second of the required three centers in its FDA clinical study of the ProUroScan Imaging System has completed its portion of the study. ProUroCare began the current study with the objective of enrolling at least 10 patients in three sites and having more than 40 patients enrolled overall. Since beginning, five clinical sites have been established, and as of last week, 44 patients have already been enrolled. The last of the three clinical studies to have 10 patients or more enrolled has only four patients remaining to meet their study objectives. ProUroCare expects to have 50 or more patients evaluated for their FDA submission, which is planned for fourth quarter 2009.
PUMD Competitors
| Company | Last | Change | |
| No competitor information is available for PUMD. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | PUMD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
PUMD |
||
PUMD transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About ProUroCare Medical Inc.
More news for PUMD
PROUROCARE MEDICAL INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation. The accompanying Management's Discussion and Analysis of Financial Condition and Results of Operation should be read in conjunction with our unaudited consolidated financial statements, and notes thereto, filed with this Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. Disclosure Regarding Forward-Looking Statements Certain statements contained in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, and the Company intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements relate to, among other things: general economic or industry conditions, nationally and in the physician, urology and medical device communities in which we intend to do business; our ability to raise capital to fund our 2009 and 2010 working capital needs and introduce our products into the marketplace; our ability to complete the development of our existing and proposed products on a timely basis or at all; legislation or regulatory requirements, including our securing of all U.S. Food and Drug Administration ("FDA") and other regulatory approvals on a timely basis, or at all, prior to being able to market and sell our products in the United States; competition from larger and more well established medical device companies and other competitors; the development of products that may be superior to the products offered by us; securing and protecting our intellectual property and assets, and enforcing breaches of the same; clinical results not anticipated by management of the Company; the quality or composition of our products and the strength and reliability of our contract vendors and partners; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; ...Click here to read the whole Article (external link)
ProUroCare Medical Inc. Announces Closing on $1.6 Million Warrant Replacement Offering
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--ProUroCare Medical Inc. (OTCBB: PUMD - News) (OTCBB: PUMDU - News) (OTCBB: PUMDW - News) today announced the successful completion of its tender offer to holders of certain outstanding warrants, resulting in gross proceeds to the Company of $1.6 million. Under the offer, the terms of the warrants were temporarily modified so that holders who exercised their warrants by November 6, 2009 would receive, in addition to the shares of common stock purchased upon exercise, an equal number of three-year replacement warrants. The replacement warrants are exercisable at $1.30 per share and may be called at ProUroCare’s discretion at any time after the last sales price of its common stock equals or exceeds $4.00 per share for ten consecutive trading days. Warrants to purchase more than 1.2 million shares were tendered pursuant to the offer. Proceeds from the of...Click here to read the whole Article (external link)
ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
MINNEAPOLIS, Oct. 8 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD - News and PUMDU - News) today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE). The results of the clinical study will be submitted to the U.S. Food and Drug Administration (FDA) in support of a 510(k) application in the near future after third party validation of the data. Urology, 168 patients were assessed using the ProUroScan system to demonstrate the technology's ability to provide an objective and reproducible image or map of the prostate. In an ensuing meeting with the FDA, a modified clinical study was discussed which would involve imaging at least 40 patients using an enhanced version of the ProUroScan imaging system.This study, which closed on September 25 with support from Artann Laboratories, ultimately included 57 patients recruited at the following medical centers:Urology," said Rick Carlson, CEO...Click here to read the whole Article (external link)
Chairman Buys $55K Worth of Enterprise Products LP
Stock quotes in this article: EPD , ASPM , PRGO , ...Click here to read the whole Article (external link)
Chairman Buys $553K Worth of Enterprise Products LP
Stock quotes in this article: EPD , ASPM , PRGO , ...Click here to read the whole Article (external link)
PROUROCARE MEDICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
Show all filings for PROUROCARE MEDICAL INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for PROUROCARE MEDICAL INC. 28-Sep-2009Entry into a Material Definitive Agreement, Creation of a Direct Financia Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). Al...Click here to read the whole Article (external link)
ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
MINNEAPOLIS--(BUSINESS WIRE)--ProUroCare Medical Inc. (OTCBB: PUMD - News) (OTCBB: PUMDU) (OTCBB: PUMDW - News) today announced that it has commenced a tender offer to holders of certain outstanding warrants to provide additional consideration for the exercise of such warrants. The warrants subject to the tender offer are 3,050,000 publicly traded warrants and 3,058,381 unregistered warrants to purchase common stock that were issued on January 12, 2009. The tender offer commenced on Friday, September 25, 2009. ProUroCare is offering to holders of the subject warrants the opportunity to exercise their existing warrants and receive, in addition to the shares of common stock purchased upon exercise, new, three-year replacement warrants. The replacement warrants will be redeemable at ProUroCare’s discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days, compared to the $1.82 redemption trigger for the existing warrants. The exercise price of both the existing warrant and the replacement warrant is $1.30 per share. Pro...Click here to read the whole Article (external link)
PROUROCARE MEDICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
Show all filings for PROUROCARE MEDICAL INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for PROUROCARE MEDICAL INC. 22-Sep-2009Entry into a Material Definitive Agreement, Creation of a Direct Financia Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informa...Click here to read the whole Article (external link)
PROUROCARE MEDICAL INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
ProUroCare Medical Announces Extension of Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
MINNEAPOLIS--(BUSINESS WIRE)--ProUroCare Medical Inc. (OTCBB: PUMD - News) (OTCBB: PUMDU - News) (OTCBB: PUMDW - News) today announced that it is extending the offering period of its current tender offer to holders of certain outstanding warrants, to provide additional time to review amended offering materials. The offer, which commenced on Sept 25, 2009, was originally scheduled to expire on Oct 30, 2009 and is now scheduled to expire at 1:00 P.M. Central Time on Nov 6, 2009. The offer extension was made as a result of the Company’s decision to amend its registration statement on a different form in response to communications from the SEC. The new form requires the Company to provide certain information within the Offer Letter/Prospectus itself that was formerly incorporated from previous...Click here to read the whole Article (external link)
Would you like to leave a comment about ProUroCare Medical Inc. PUMD/PUMD.OB
Find out what social network information about ProUroCare Medical Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides ProUroCare Medical Inc. there is more great information available at Realpennies.com